Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 5Recruiting 2Completed 2Active not recruiting 2Withdrawn 1No longer available 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 1

Interventions

pembrolizumab 185Carboplatin 133Paclitaxel 102Cisplatin 102Gemcitabine 86Pemetrexed 80durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 42Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × loncastuximab tesirine × Clear all
NCT04384484 2026-04-28

LOTIS 5

ADC Therapeutics S.A.

Phase 3 Active not recruiting
440 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05658562 2026-02-13

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Tanabe Pharma Corporation

Phase 1/2 Active not recruiting
46 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡